Selective B cell depletion upon intravenous infusion of replication-incompetent anti-CD19 CAR lentivirus

Anti-CD19 chimeric antigen receptor (CAR)-T therapy for B cell malignancies has shown clinical success, but a major limitation is the logistical complexity and high cost of manufacturing autologous cell products. If engineered for improved safety, direct infusion of viral gene transfer vectors to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Rive, Craig M., Yung, Eric, Dreolini, Lisa, Brown, Scott D., May, Christopher G., Woodsworth, Daniel J., Holt, Robert A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198363/
https://www.ncbi.nlm.nih.gov/pubmed/35755944
http://dx.doi.org/10.1016/j.omtm.2022.05.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198363/
https://www.ncbi.nlm.nih.gov/pubmed/35755944
http://dx.doi.org/10.1016/j.omtm.2022.05.006

Ejemplares similares